Cargando…

Tenofovir Concentration Is Not Enough in Intraocular Tissues of Patients With HIV infection

To determine tenofovir (TFV) penetration into intraocular tissues using ultra high-performance liquid chromatography/tandem mass spectrometry (UHPLC-MS/MS). METHODS: Nineteen participants taking tenofovir in combination antiretroviral therapy (cART) regimen who underwent pars plana vitrectomy (PPV)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Yiwen, Wang, Luoziyi, Xing, Yaru, Yin, Lin, Jiang, Jing, Suo, Jinshan, Che, Xin, Zhang, Lijun, Wang, Zhiliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2023
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069752/ https://www.ncbi.nlm.nih.gov/pubmed/36881850 http://dx.doi.org/10.1097/QAI.0000000000003171

Ejemplares similares

Isolation and Characterization of Primary Retinal Microglia From the Human Post-mortem Eyes for Future Studies of Ocular Diseases
por: Wang, Luoziyi, et al.
Publicado: (2022)

Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series
por: Qian, Yiwen, et al.
Publicado: (2022)

Endophthalmitis caused by Mycobacterium houstonense: case report
por: Che, Xin, et al.
Publicado: (2020)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Choroidal and retinal thickness in patients with vitamin C deficiency using swept-source optical coherence tomography
por: Qian, Yiwen, et al.
Publicado: (2022)

Idiopathic Epiretinal Membrane Surgery in Patients Aged Over 80 Years: Efficacy and Safety
por: Li, Qingjian, et al.
Publicado: (2023)

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
por: Liu, Zhihong, et al.
Publicado: (2021)

Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
por: Ouattara, Louise A., et al.
Publicado: (2022)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
por: Else, Laura, et al.
Publicado: (2022)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients
por: Aragonès, Gerard, et al.
Publicado: (2012)

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
por: Raffi, François, et al.
Publicado: (2017)

Associations between plasma tenofovir concentration and renal function markers in HIV-infected women
por: Mulubwa, Mwila, et al.
Publicado: (2016)

Case report-immune recovery posterior scleritis in a HIV positive patient
por: Che, Xin, et al.
Publicado: (2020)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
por: Gupta, Samir K., et al.
Publicado: (2019)

The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
por: Solomon, Marc M., et al.
Publicado: (2016)

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
por: Perez-Valero, Ignacio, et al.
Publicado: (2021)

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
por: Donnell, Deborah, et al.
Publicado: (2014)

Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials
por: Orkin, Chloe, et al.
Publicado: (2021)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
por: Solomon, Marc M., et al.
Publicado: (2014)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

Control of HIV viraemia is not enough in perinatal HIV
por: Foster, Caroline, et al.
Publicado: (2015)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

Enough is enough
por: Borowski, Christine
Publicado: (2011)

Enough Is Enough
por: Dietz, Rob
Publicado: (2012)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis
por: Mirembe, Brenda G., et al.
Publicado: (2016)

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I
por: Sax, Paul E., et al.
Publicado: (2022)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

When Is Enough, Enough?
por: Ng, Perryn, et al.
Publicado: (2020)

Why “good enough” is not good enough: scientific data, not supply chain deficiencies, should be driving Centers for Disease Control and Prevention recommendations
por: Morgan, Elizabeth A., et al.
Publicado: (2020)

Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough
por: Larson, Bruce A., et al.
Publicado: (2013)

Lamina cribrosa pore movement during acute intraocular pressure rise
por: Wang, Ya Xing, et al.
Publicado: (2020)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vu8776g77visn4al7lur5rsi74